Immunotherapy: 424 Real Stories

424 stories match immunotherapy. 352 of them mention chemotherapy.

A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

A young man with metastatic rectal cancer and inherited BRCA1 and MLH1 mutations

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: Germline BRCA1 c.4065_4068delTCAA and MLH1 c.232G>T mutations; tumor microsatellite instability-high; loss of MLH1 and PMS2 expression; elevated tumor mutational burden; loss of heterozygosity of wild-type MLH1.

Metastatic Site: liver

The rectal and liver tumors showed a partial response, no viable carcinoma was found in the resected liver lesions, and maintenance nivolumab continued without evidence of growth or recurrence.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Metastatic hepatoid gastric adenocarcinoma achieving complete remission with sintilimab

Patient Info: Anonymized, male | Stage IV

Biomarkers: AFP markedly elevated

Metastatic Site: liver

By the fifth sintilimab cycle, gastroscopy showed no gastric tumor, CT showed no liver metastases and AFP had normalized; complete remission was confirmed and remained stable during subsequent treatment.

PubMed Central
OutcomeCancer-Free / NED
Cindi, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Cindi's Survivor Story

Patient Info: Cindi, Female, 60s | Stage IV

Metastatic Site: Liver; abdominal lining/peritoneum

As of March 2022, Cindi had no recurrence more than 1 year after a clinical trial with nivolumab, investigational anti-tumor vaccine, chemotherapy, and surgery produced a complete pathologic response with no living cancer cells.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed Central
OutcomeResponding Well
Eve, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Eve's Patient Story

Patient Info: Eve, Female, 40s

As of 2022, Eve was facing unstaged breast cancer and receiving care after her plan changed to mastectomy, lymphadenectomy, and immunotherapy.

Our Cancer Stories
OutcomeCare Ongoing
Edith, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Edith's Patient Story

Patient Info: Edith | Stage III

Edith said her breast cancer was in remission while she continued hormone therapy; she had also begun separate treatment for lymphoma.

Our Cancer Stories
OutcomeCare Ongoing
Martha, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Martha's Patient Story

Patient Info: Martha | Stage II

Martha underwent multimodal treatment for stage II breast cancer and remained focused on living, supporting others, and seeing her son build a fulfilling life.

Our Cancer Stories
OutcomeNot reported
Li, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Li's Patient Story

Patient Info: Li Zong

Li Zong remained on chemotherapy and targeted therapy while considering future hospice and palliative care.

Our Cancer Stories
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Long-term complete response to nivolumab after recurrent Stage IV gastric cancer

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: HER2-negative, PD-L1 CPS ≤1

Metastatic Site: peritoneum, distant lymph nodes

About 7 years after surgery and roughly 3 years after starting nivolumab, CT showed no recurrent nodules or enlarged lymph nodes. She remained on nivolumab with a complete clinical response, had regained weight and returned to work.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed Central
OutcomeStable Disease
Abby, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Abby's Survivor Story

Patient Info: Abby Kanarek, Female, 60s | Stage IV

Biomarkers: PD-L1 90%

Metastatic Site: Brain

As of November 2021, Abby was in remission 2 years after only 4 Keytruda infusions, with the lung cancer eliminated and ongoing surveillance by a multidisciplinary City of Hope team.

City of Hope
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Kidney Injury During Nivolumab Treatment for Stage IV Gastric Cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Kidney function and proteinuria improved after nivolumab was stopped, but the gastric cancer progressed. Restarted nivolumab was ineffective, and treatment was changed to irinotecan.

PubMed Central
OutcomeSetback / Progression
Steve, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Steve's Patient Story

Patient Info: Steve Castellaw, 70+ | Stage IV

Metastatic Site: right pelvis, L1 and L2 vertebrae, skull

After about 2 years on sotorasib, Steve had a large reduction in tumor size and his latest scans continued to look good while he returned to golf, exercise, and normal daily life.

AACR
OutcomeResponding Well
Tammy, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I HER2-Positive Invasive Ductal Carcinoma: Tammy's Patient Story

Patient Info: Tammy, Female | Stage I

Biomarkers: HER2-positive; triple-positive breast cancer

As of September 2021, this story segment described the start of Tammy’s adjuvant treatment plan after HER2-positive, triple-positive Stage I invasive ductal carcinoma was found; no later outcome was stated in this record.

YouTube — Tammy Salamone - The Pink Survivor
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

A Severe Delayed Immune Reaction After Treatment for Metastatic Colon Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver

He recovered from repeated episodes of severe cytokine release syndrome after prolonged corticosteroids, completed adjuvant FOLFOX and CV301 without nivolumab, and had no further CRS episodes.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

MSI-High Malignant Struma Ovarii With Lung and Liver Metastases 17 Years Later

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRAS, and ATM mutations; Ki-67 approximately 15%–29%

Metastatic Site: lungs|liver

She remained asymptomatic and tolerated pembrolizumab without obvious adverse effects after 4 doses, with follow-up imaging planned for metastatic lung and liver disease.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Immunotherapy and surgery for lung adenocarcinoma with two brain metastases

Patient Info: Anonymized, Female, 50s

Biomarkers: PD-L1 100%; no actionable mutations on next-generation sequencing.

After brain surgery, radiation, 11 cycles of pembrolizumab, and lung surgery, she was off treatment and under observation in remission.

PubMed Central
OutcomeCancer-Free / NED